Study S002573

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study of TG103 Injection in the Management of Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05299697
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: UNKNOWN
Enrollment: 195
Start: 2022-05-20
Primary completion: 2023-06-30
Lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions: Overweight or Obesity
Interventions: DRUG:TG103 15 mg; DRUG:TG103 22.5 mg; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Relative change from baseline in body weight at week 24 [From baseline to week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.